Calcigenol

Quick links to important sections

Calcigenol

Method of action: Mineral Supplements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcigenol

Quick Facts

Property Description
Active Ingredients Tricalcium Phosphate, Cholecalciferol (Vitamin D3)
Form Oral Liquid (Syrup or Colloidal Suspension)
Pharmacological Class Mineral Supplement, Recalcifying Tonic
Common Use Support for Bone Health and Mineral Homeostasis
Origin Synthetic/Derived

Defining Calcigenol: Type, Class, and Purpose

Calcigenol is classified fundamentally as an Oral Liquid Dietary Supplement, primarily falling within the pharmacological class of Mineral Supplements and often functioning as a Recalcifying Tonic. The general purpose of this combination product is the delivery of essential inorganic entities to support Bone health and maintain physiological mineral homeostasis. This product is designed as a foundational support agent to aid in the prevention and management of common Calcium deficiency states. The utility of this Recalcifying action is clinically recognized for supporting mineral balance in high-demand patient groups, such as growing children or lactating women.

Composition and Form: Tricalcium Phosphate and Cholecalciferol

The formulation of Calcigenol is a multi-component Combination Product administered via the Oral route. The central Active ingredient is Tricalcium Phosphate (Ca3(PO4)2), which is recognized by its ability to deliver both the Calcium and Phosphorus entities simultaneously. This dual-mineral source is a key differentiating factor from simple calcium-only supplements. Many preparations, such as Calcigenol D, incorporate Cholecalciferol (Vitamin D3). The necessity of this combination is widely supported by nutritional science: Vitamin D is essential for facilitating the intestinal absorption of the Calcium entity by the body, ensuring the mineral's bioavailability. Calcigenol is positioned for its convenient Syrup or Colloidal Suspension form, which makes the Oral Liquid suitable for individuals who have difficulty swallowing solid dosage forms.

Regulatory References

  1. Calcium | MedlinePlus

What side effects are possible with Calcigenol?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of Calcigenol (Tricalcium Phosphate and Cholecalciferol) primarily around the established risks associated with supplemental mineral and vitamin D intake.

Adverse Reaction Scope

The most commonly listed adverse reactions relate to the Gastrointestinal System. These reactions, which include constipation, nausea, vomiting, flatulence, and stomach bloating, are often documented in regulatory summaries. The precise frequency classification (e.g., Common, Uncommon) for these reactions is often reported as Not Known in general-use product information.

Serious Adverse Reactions and Systemic Risks

The most significant safety concerns documented are related to metabolic balance. Hypercalcemia (abnormally high blood calcium levels) is officially classified as a serious adverse reaction. This condition, typically associated with prolonged or high-dose use, carries a further systemic risk for complications in the Renal and Urinary Disorders system, particularly the formation of Nephrolithiasis (kidney stones). Additionally, the possibility of a severe Allergic Reaction (hypersensitivity) is noted in the overall safety profile.

Population-Specific Safety Constraints

The official label states that Calcigenol is contraindicated in individuals with pre-existing conditions of Hypercalcemia or Hypervitaminosis D. Caution is also documented as being necessary for patients with kidney disease or a known history of kidney stones. Furthermore, use during pregnancy and lactation must be carefully managed to ensure the dosage does not exceed the recommended daily allowance, as per official government guidelines.

This safety information establishes that while common effects are generally non-serious, the critical focus for the medicine's risk management is the potential for elevated calcium levels.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory description of Calcigenol overdose is based on the risk of Hypervitaminosis D and the resulting Hypercalcemia and Hyperphosphatemia due to the excess intake of Vitamin D and Calcium. Documented manifestations include gastrointestinal effects such as nausea, vomiting, and constipation, alongside systemic signs like polyuria, polydipsia (increased thirst), muscle weakness, and mental disturbances. Laboratory findings consistently show elevated serum calcium and phosphate levels.

Severe outcomes officially listed in the regulatory profile involve a significant risk of cardiac arrhythmias and irreversible renal damage, specifically Nephrocalcinosis. In the event of a suspected overdose, regulatory guidance mandates that immediate medical attention must be sought. Urgent medical services must be contacted immediately if severe signs, such as collapse or seizures, are observed.

No specific antidote is known for this type of overdose. Management is officially described as supportive and procedural, requiring the immediate discontinuation of Calcigenol intake. Supportive measures listed in regulatory documentation include intravenous rehydration and intensive monitoring of serum calcium levels until normalization. Close clinical monitoring, including ECG, is required in severe cases. Special consideration is noted for patients with renal impairment, who require diligent monitoring of calcium and phosphate levels.

Therapeutic Uses of Calcigenol

What Calcigenol Treats: Main Uses and Benefits

Calcigenol is primarily used for its supportive benefits across clinical scenarios associated with symptoms that create noticeable physiological strain and the related discomfort. The therapeutic scope is applied to conditions where supportive management of systemic or localized discomfort is appropriate, helping patients cope more steadily with periods of heightened symptoms.

Calcium supplements are commonly used to help manage symptoms associated with conditions that interfere with daily functioning, generally assisting with maintaining functional stability during symptomatic periods. Calcigenol may be relevant when symptoms become more disruptive during flare-ups, and is applied in clinical settings that involve acute or unstable symptom patterns.

It helps address groups of symptoms that may appear suddenly or intensify over time, such as those related to heightened physiological activity or strain. Often used when symptoms intensify and supportive relief is needed, Calcigenol may be applied during phases when the patient experiences increased distress or discomfort.


Therapeutic Applications

Calcigenol is used for managing conditions characterized by episodic or fluctuating manifestations, applied across domains where additional symptomatic support is needed, and is relevant in situations involving recurrent or episodic manifestations.


Quick Fact

Quick Fact: Support for Symptomatic Discomfort

Calcigenol helps address groups of symptoms that may become intense or disruptive and interfere with daily comfort.

Regulatory References

  1. Calcium Supplements

Eligibility and Restrictions for Use

The official regulatory eligibility for Calcigenol is primarily determined by absolute population exclusions related to mineral and vitamin toxicity. The medicine is strictly contraindicated in patients presenting with pre-existing Hypercalcaemia (high blood calcium), Hypercalciuria (high urine calcium), or Hypervitaminosis D (excess Vitamin D). Use is also prohibited for individuals with known hypersensitivity to the active components or those with severe renal insufficiency, as their impaired function compromises the safe clearance of calcium and phosphate.

For other populations, use is conditional and requires caution. Patients with mild to moderate renal impairment, a history of kidney stones, or a condition like Sarcoidosis must be closely monitored. Age-related use is generally permitted for children to prevent deficiency; however, high-dose formulations are typically not recommended for those under 18. During pregnancy and breastfeeding, use is allowed within normal daily limits, but regulatory guidance emphasizes that overdose must be strictly avoided due to potential fetal harm from resulting hypercalcaemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Calcigenol, a combination of Tricalcium Phosphate (Calcium) and Cholecalciferol (Vitamin D3), is structured around absorption interference and effects on mineral exposure.

Interaction Classifications and Constraints

Category Documented Interaction Pattern
Formal Restriction Co-administration with other Vitamin D analogs is contraindicated due to the risk of additive effects leading to hypercalcemia.
Exposure Alteration Phenytoin and Fosphenytoin are documented to increase the catabolism of cholecalciferol, potentially reducing Vitamin D exposure.
Pharmacodynamic Risk Thiazide diuretics may decrease the renal excretion of calcium, creating a risk for elevated calcium levels. If hypercalcemia occurs, the risk of cardiotoxicity with Cardiac Glycosides increases.

Timing-Based Administration Rules

Calcigenol's calcium content can interfere with the absorption of other medicines via chelation, requiring separated dosing. Mandatory separation is necessary for Tetracycline and Quinolone antibiotics, Oral Bisphosphonates, and Levothyroxine to ensure adequate exposure of these co-administered drugs. Regulatory information advises specific spacing between administrations. Additionally, foods high in Oxalic or Phytic acid are documented to reduce the absorption of the calcium component.

Mechanism of Action

Modulation of Vitamin D Receptor Signaling

Calcigenol, a complex that includes Cholecalciferol (Vitamin D3), functions as a ligand for the Vitamin D Receptor (VDR) in target cells. This interaction facilitates the binding of the VDR to specific DNA response elements, thereby initiating or suppressing the transcription of target genes. This gene-level modulation is central to controlling the synthesis of calcium-binding proteins and other intermediate mediators, which influences regulatory processes within key metabolic pathways.

Regulation of Intestinal and Renal Ion Transport

The activation of the VDR pathway specifically governs the expression of ion transporters, primarily in the small intestine and the renal tubules. In the intestine, this activity promotes the absorption of dietary calcium. Concurrently, in the kidney, it increases the renal tubular reabsorption of calcium. This mechanism influences the flux of calcium ions across biological membranes, contributing directly to the maintenance of systemic calcium ion concentration.

Influence on Skeletal Mineral Dynamics

At the skeletal level, Calcigenol engages in cascades that modulate bone turnover. By influencing molecular steps within bone cells, the mechanism regulates the differentiation and activity of osteoblasts (bone formation) and, indirectly, osteoclasts (bone resorption), thereby influencing the controlled exchange of calcium with the skeletal stores.

Dosage and Administration Information

Calcigenol is approved exclusively for oral administration as a liquid suspension or syrup, which is the only authorized route. The formulation’s structure is designed to deliver a measured volume, making it suitable for accurate dosing and ease of intake.


The dosing schedule is based on the required daily intake of Elemental Calcium, typically ranging from 500 mg to 1000 mg, along with the corresponding units of Cholecalciferol (Vitamin D3). This total amount is generally taken on a daily basis, and may be administered as a single dose or divided into two separate doses to optimize the absorption of the mineral component.

To ensure proper usage, the container must be shaken well immediately before measuring the dose, and the required volume must be measured accurately using the calibrated device provided. A crucial administration condition is the timing: Calcigenol is intended to be taken with or immediately following a main meal, as this context facilitates the intestinal uptake of the active ingredients.

Usage rules are modified for specific patient groups. Pediatric patients require the dose to be carefully adjusted based on their age and body weight. Additionally, individuals with renal impairment are subject to close clinical and biochemical monitoring while using the product. If a dose is missed, standard instructions are to take it as soon as it is remembered. However, if the timing is near the next scheduled dose, the missed dose should be skipped entirely, and the user must not take a double dose to compensate.

Recent Clinical Evidence

Calcigenol: Recent Clinical Evidence


Evidence for Use in Bone Mineral Density and Fracture Prevention

Research has primarily examined the combined active ingredients in relation to skeletal integrity, especially in populations at risk of mineral loss. Large-scale Randomized Controlled Trials (RCTs) monitored outcomes such as Bone Mineral Density (BMD), the incidence of hip and non-vertebral fractures, and blood concentrations of Vitamin D. Studies tracked measurements of BMD and described patterns such as stabilization or increase over long-term durations (2–5 years) in certain high-risk elderly populations. Clinical reports followed fracture incidence, with findings showing variability based on the specific patient group and baseline vitamin D status.

Long-term data on fracture outcomes and durability are not yet fully established across all community-dwelling adult populations. Research is ongoing, but data for certain groups remain insufficient to draw general conclusions, and subgroup findings are uncertain in healthy, general adult populations.


Evidence for Systemic Supportive Management

Research explored how the Vitamin D component was evaluated in people experiencing systemic physiological strain or imbalance. RCTs monitored outcomes including all-cause mortality, ICU stay duration, and levels of inflammatory biomarkers like CRP and IL-6. Studies reported how inflammatory markers evolved, but consistent patterns were not observed for the core systemic markers across many trials. The evidence is limited because studies focusing on these outcomes often relate only to the Vitamin D component in isolation, and follow-up durations were typically short-term.


Research Gaps and Areas of Uncertainty

The evidence landscape is characterized by several limitations. For the primary indication, findings were mixed regarding the effectiveness on all fracture types, and results apply most consistently to high-risk groups, meaning that results show variability across studies. For the systemic supportive indication, certainty remains low due to inconsistent findings and heterogeneity across trials. Long-term effects are not fully established in all populations, and the current evidence contributes to the broader landscape but leaves several specific questions unanswered.

Key Studies & References The Anti-Inflammatory Roles of Vitamin D for Improving Human Health (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Calcigenol (FAQ)

Q: I heard that Calcigenol interacts with a specific type of food—is that true?

A: Official information states that certain types of food can interfere with how your body absorbs Calcigenol. Specifically, foods containing high amounts of Oxalic acid (such as spinach) or Phytic acid (found in certain whole grains) are documented to reduce the absorption of the calcium component. Regulatory guidance notes that the administration timing may need to be separated from the consumption of these foods.

Q: Is Calcigenol suitable for people over the age of 65?

A: Official documents indicate that the use of Calcigenol is generally suitable for adults, and the active ingredients have been included in studies focused on older adults. Dosage requirements for individuals over 65 are standard for adults, provided the patient meets the official eligibility criteria for use.

Q: How does Calcigenol affect blood levels of [specific substance/marker]?

A: The product is designed to support the maintenance of normal blood concentrations of both Vitamin D and Calcium in the body. However, official safety information indicates that if excessive amounts are taken, a condition called Hypercalcemia (abnormally high blood calcium levels) may occur. Therefore, usage requires careful management in alignment with regulated guidelines.

Q: What types of safety monitoring are described for people using Calcigenol?

A: Regulatory guidance focuses on ensuring safe use by detailing specific safety monitoring requirements for certain patient groups. For example, individuals with impaired kidney function must undergo close clinical and biochemical monitoring. This monitoring typically involves checking blood markers such as serum calcium and phosphorus levels.

Q: Can someone with a history of heart problems use Calcigenol?

A: The regulatory profile for Calcigenol notes an interaction concern related to heart function. Specifically, the risk of cardiotoxicity (potential harm to the heart) is described as increasing if high blood calcium (Hypercalcemia) occurs, particularly for people taking Cardiac Glycosides (a type of heart medicine).

Q: Is Calcigenol considered a preventative treatment?

A: Official regulatory sources position Calcigenol as a supportive agent intended to help with the long-term maintenance of the body's mineral balance. Its use is described as aiding in the prevention and management of common calcium deficiency states.

Q: Is it normal to feel a change in appetite while using Calcigenol?

A: Loss of appetite (anorexia) is not listed as a common, mild side effect, but rather as a potential symptom of Hypercalcemia (abnormally high blood calcium). Hypercalcemia is a serious adverse reaction listed in official safety documents that can occur with prolonged or excessive use.

Q: Why do some people say Calcigenol made them feel tired?

A: Fatigue and generalized muscle weakness are described in regulatory documents as possible symptoms associated with Hypercalcemia (abnormally high blood calcium). This condition is considered a serious adverse reaction to Calcigenol, typically linked to prolonged or high-dose use.

Q: Can Calcigenol cause weight gain or loss?

A: Official safety information lists weight loss as a potential symptom of Hypercalcemia, which is a serious, metabolic adverse reaction. Hypercalcemia is associated with prolonged or excessive intake of the product.

Q: Are there any known interactions between Calcigenol and common vitamins?

A: The official interaction profile includes a warning against combining Calcigenol with similar supplements. Co-administration with other Vitamin D analogs is strictly contraindicated due to the risk of additive effects. Official guidance notes that the addition of other supplements containing Vitamin D or Calcium requires professional supervision.

Q: Can men and women use Calcigenol for the same conditions?

A: Yes, the official indications for Calcigenol are based on the underlying mineral deficiency and the need for mineral homeostasis, rather than the patient's sex. The use of the product to support bone health applies to adults generally.

Q: Can Calcigenol be taken if I am lactose intolerant?

A: Regulatory documents require that all excipients (inactive ingredients) in the liquid suspension be listed. If the formulation contains ingredients like lactose or certain sugars, a specific patient warning would be included in the official label to inform individuals with intolerance or sensitivity.

Q: Is Calcigenol a type of hormone replacement?

A: No, Calcigenol is fundamentally classified as a Mineral Supplement and a Recalcifying Tonic in official documents. Although it contains Cholecalciferol (Vitamin D3), which influences the Vitamin D Receptor, it is not considered a hormone replacement therapy.

Q: Are there any special considerations for people with diabetes using Calcigenol?

A: Because Calcigenol is an oral liquid, the official regulatory label must disclose whether the formulation contains sucrose (sugar) or other carbohydrates. This information is provided so that patients managing diabetes can take the product's carbohydrate content into consideration.

Q: Can you drive or operate machinery while using Calcigenol?

A: Official regulatory documents typically contain a section addressing the impact of the medicine on daily life activities. They generally state that Calcigenol has no or negligible influence on the ability to drive or operate machinery.

Q: Is Calcigenol known to cause any skin reactions?

A: The overall safety profile notes the possibility of a severe Allergic Reaction (hypersensitivity), which may involve skin symptoms. Additionally, certain skin changes or rashes can occur as a symptom of Hypercalcemia, which is a serious adverse reaction associated with excessive use.

Q: Does alcohol interact with Calcigenol?

A: Official regulatory documents often include a statement about alcohol use. They either state that no specific studies on interactions with alcohol have been performed or list high alcohol consumption as a potential risk factor related to general health while using the medication.

Q: Why is it necessary to take Calcigenol for an extended period?

A: The medication is intended to support the body's long-term structure and balance. Regulatory documents indicate the product is used to support long-term bone health and maintain physiological mineral homeostasis, which often necessitates consistent use.

Q: What is the reason for needing to check blood levels before starting Calcigenol?

A: Blood tests are important because regulatory guidelines strictly prohibit use in patients with certain pre-existing conditions. Specifically, blood levels are checked to rule out Hypercalcemia (abnormally high blood calcium) or Hypervitaminosis D (excess Vitamin D), which are strict contraindications.

Q: Does Calcigenol only work for one specific medical condition?

A: No, the official indications for Calcigenol cover multiple related aspects of mineral balance. The product is described as providing support for Bone Health, maintaining Mineral Homeostasis, and assisting with the management of common Calcium deficiency states.

How should Calcigenol be stored and disposed of?

How to Store and Dispose of Calcigenol

Official regulatory labeling dictates strict conditions to maintain the stability and safety of Calcigenol (Calcium Carbonate Oral Suspension).


Storage Requirements

The product must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). It is essential to do not freeze the suspension and to protect the container from excess heat and moisture. The liquid must be shaken well before using to ensure uniform dispersion of the active ingredients. Keep the medication in the container it came in, tightly closed.


Safety and Disposal

Calcigenol must be stored out of the sight and reach of children. The regulatory documents state that unused or expired Calcigenol must be disposed of following local regulations for pharmaceutical waste, rather than being placed in household trash or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcigenol found in:

A-Z Index: